{'fraction_non_alphanumeric': 0.02680067001675042, 'fraction_numerical': 0.006700167504187605, 'mean_word_length': 5.294736842105263, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Screening of new protease inhibitors with application in the treatment of HCV infections non-responsible to the direct-action antivirals

Introduction: Hepatitis C is a disease with a global prevalence of 3% of cases of hepatitis C virus (HCV) infection, which corresponds to 130 million infected people worldwide. Recently, new drugs have emerged for the treatment of HCV infection with fewer side effects and greater efficacy, composing direct action antivirals (DAA) regimens. However, the search for new antiviral agents continues to be necessary due to HCV Infections non-Responsible to them.